Possibility of potential risk for humans (animal studies shown developmental toxicity). Organ transplant patients. May affect ability to drive & use machines. Severe hepatic impairment. Women of childbearing potential should use appropriate contraception during treatment & continue for 1-mth after discontinuation. Not recommended during pregnancy & lactation. Not to be prescribed in paed population.
May inhibit intestinal activities of UGT1A1. May potentially inhibit efflux transporter BCRP & may increase systemic exposure of its substrates (eg, MTX, rosuvastatin, imatinib). Assess patients receiving BCRP & OAT substrates as exposure to these drugs may be increased. May decrease serum conc of total thyroxine w/o an accompanying change in free thyroxine or TSH.
Sign Out
